Targeting HPV16 DNA using CRISPR/Cas inhibits anal cancer growth in vivo.

Published

Journal Article

Aim: The goal of this study was to determine if a single AAV vector, encoding Cas9 and guide RNAs specific for the HPV16 E6 and E7 genes, could inhibit the growth of an HPV16-induced tumor in vivo. Materials & methods: We grew HPV16+, patient-derived anal cancer explants in immunodeficient mice and then challenged these by injection of AAV-based vectors encoding Cas9 and control or HPV16-specific guide RNAs. Results & conclusion: We observed a significant and selective reduction in tumor growth when the HPV16 E6 and E7 genes were targeted using Cas9. These studies provide proof of principle for the hypothesis that CRISPR/Cas has the potential to be used to selectively treat HPV-induced tumors in humans.

Full Text

Duke Authors

Cited Authors

  • Hsu, DS; Kornepati, AV; Glover, W; Kennedy, EM; Cullen, BR

Published Date

  • July 2018

Published In

Volume / Issue

  • 13 / 7

Start / End Page

  • 475 - 482

PubMed ID

  • 30245733

Pubmed Central ID

  • 30245733

International Standard Serial Number (ISSN)

  • 1746-0794

Digital Object Identifier (DOI)

  • 10.2217/fvl-2018-0010

Language

  • eng

Conference Location

  • England